Damora Therapeutics (DMRA) Income towards Parent Company (2019 - 2026)

Damora Therapeutics' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$27.8 million for Q1 2026.

• Quarterly Income towards Parent Company fell 996.84% year-over-year to -$27.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$231.2 million (down 1150.22% YoY) and the FY2025 annual result came in at -$206.0 million, down 860.77% from the prior year.
• Income towards Parent Company was -$27.8 million for Q1 2026 at Damora Therapeutics, up from -$196.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $1.7 million in Q4 2023 and bottomed at -$196.9 million in Q4 2025.
• A 5-year average of -$20.5 million and a median of -$8.1 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company surged 112.19% — and 2025, when it plunged 2820.58%.
• Damora Therapeutics' Income towards Parent Company stood at -$13.7 million in 2022, then jumped by 112.19% to $1.7 million in 2023, then plunged by 504.38% to -$6.7 million in 2024, then plunged by 2820.58% to -$196.9 million in 2025, then surged by 85.89% to -$27.8 million in 2026.
• Business Quant data shows DMRA's Income towards Parent Company at -$27.8 million in Q1 2026, -$196.9 million in Q4 2025, and -$3.1 million in Q3 2025.